CVS Caremark has agreed to pay $45 million to settle allegations that rebates were not passed through properly in Illinois. Pfizer’s gene therapy for hemophilia A showed promise in reducing patient bleeds, but doubts remain about its ability to provide a cure or meaningful treatment option. The data may be enough for approval, but experts question its superiority over a similar treatment from BioMarin. The article also mentions a STAT+ exclusive story available to subscribers, offering in-depth analysis, newsletters, premium events, and networking access. CVS Caremark’s settlement and Pfizer’s gene therapy data are highlighted as key points in the content.
Source link
We’re reading about CVS settlement, Pfizer hemophilia therapy
